Toxic effects of iron oxide nanoparticles on human umbilical vein endothelial cells.
Iron oxide nanoparticles (IONPs) have been employed for hyperthermia treatments, stem cell therapies, cell labeling, and imaging modalities. The biocompatibility and cytotoxic effects of iron oxide nanoparticles when used in biomedical applications, however, are an ongoing concern. Endothelial cells have a critical role in this research dealing with tumors, cardiovascular disease and inflammation. However, there is little information dealing with the biologic effects of IONPs on the endothelial cell. This paper deals with the influence of dextran and citric acid coated IONPs on the behavior and function of human umbilical vein endothelial cells (HUVECs). After exposing endothelial cells to IONPs, dose-dependent effects on HUVECs viability, cytoskeleton and function were determined. Both citric acid and dextran coated particles appeared to be largely internalized by HUVECs through endocytosis and contribute to eventual cell death possibly by apoptosis. Cytoskeletal structures were greatly disrupted, as evidenced by diminished vinculin spots, and disorganized actin fiber and tubulin networks. The capacity of HUVECs to form a vascular network on Matrigel™ diminished after exposure to IONPs. Cell migration/invasion were inhibited significantly even at very low iron concentrations (0.1 mM). The results of this study indicate the great importance of thoroughly understanding nanoparticle-cell interactions, and the potential to exploit this understanding in tumor therapy applications involving IONPs as thermo/chemoembolization agents.
Wu
Xinying
X
Department of Radiology, Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China.
Tan
Yanbin
Y
Mao
Hui
H
Zhang
Minming
M
D002448:Cell Adhesion / Q000187:drug effects; D002465:Cell Movement / Q000187:drug effects; D002470:Cell Survival / Q000187:drug effects; D002478:Cells, Cultured; D019343:Citric Acid; D020099:Coated Materials, Biocompatible; D003599:Cytoskeleton / Q000187:drug effects; D003911:Dextrans; D042783:Endothelial Cells / Q000187:drug effects* / Q000378:metabolism; D051416:Focal Adhesion Protein-Tyrosine Kinases / Q000378:metabolism; D006801:Humans; D058185:Magnetite Nanoparticles / Q000008:administration & dosage / Q000633:toxicity* / Q000648:ultrastructure; D046529:Microscopy, Electron, Transmission; D050997:Nanomedicine; D018919:Neovascularization, Physiologic / Q000187:drug effects; D010316:Particle Size; D014471:Umbilical Veins / Q000166:cytology / Q000187:drug effects / Q000378:metabolism
D020099:Coated Materials, Biocompatible; D003911:Dextrans; D058185:Magnetite Nanoparticles; D019343:Citric Acid; D051416:Focal Adhesion Protein-Tyrosine Kinases